Reactive oxygen species regulate the differentiation of acute promyelocytic leukemia cells through HMGB1-mediated
Liangchun Yang1, Wenwen Chai2, Yanping Wang1
1Department of Pediatrics, Xiangya Hospital, Central South University Changsha, Hunan 410008, People's Republic of China.
Abstract:
Acute promyelocytic leukemia (APL) results from a blockade of granulocyte differentiation during the promyelocytic stage. As a fusion protein of promyelocytic leukemia (PML) and retinoic acid receptor-α (RARα), PML-RARα oncoprotein is degraded through the differentiation of all-trans retinoic acid (ATRA)-induced cells. Here reactive oxygen species (ROS) and high-mobility group box 1 (HMGB1) were proven essential for the differentiation of APL cells. A down-regulation of ROS by ROS quencher (NAC) blocked the differentiation of APL cell line NB4 while an over-expression of ROS by superoxide dismutase-1 (SOD1) RNA interference (RNAi) increased cell differentiation. HMGB1 was vital for the differentiation of ROS-mediated NB4 cells and its up-regulation promoted ATRA-induced autophagy and the degradation of PML-RARα. Furthermore, ATRA treatment elevated the levels of ROS, enhanced autophagic flux and thereby promoted cytosolic translocation of HMGB1. HMGB1 regulated the interactions between ubiquitin-binding adaptor protein p62/SQSTM and PML-RARα so as to affect the degradation of PML-RARα during ATRA-induced autophagy. Also a depletion of p62/SQSTM1 expression inhibited HMGB1-mediated PML-RARα degradation and cell differentiation. The overall results suggested that HMGB1 is an essential regulator of ROS-induced cell differentiation. And it may become a potential drug target for therapeutic intervention of APL.
Insights
Reactive oxygen species (ROS) and high-mobility group box 1 (HMGB1) are crucial for acute promyelocytic leukemia (APL) cell differentiation. HMGB1, regulated by ROS, promotes PML-RARα degradation and may be a therapeutic target for APL.
Area of Science:
- Hematology
- Molecular Biology
- Cell Biology
Background:
- Acute promyelocytic leukemia (APL) is characterized by blocked granulocyte differentiation.
- The PML-RARα oncoprotein drives APL and is degraded during all-trans retinoic acid (ATRA) treatment.
- Understanding the molecular mechanisms of APL differentiation is critical for therapeutic development.
Purpose of the Study:
- To investigate the roles of reactive oxygen species (ROS) and high-mobility group box 1 (HMGB1) in ATRA-induced APL cell differentiation.
- To elucidate the molecular pathways involving ROS, HMGB1, and PML-RARα degradation.
Main Methods:
- Utilized the APL cell line NB4 and treated with ATRA.
- Manipulated ROS levels using N-acetylcysteine (NAC) and superoxide dismutase-1 (SOD1) RNA interference (RNAi).
- Assessed HMGB1 levels, autophagy, PML-RARα degradation, and p62/SQSTM1 interactions.
Main Results:
- Down-regulation of ROS inhibited NB4 cell differentiation, while over-expression enhanced it.
- HMGB1 was essential for ROS-mediated differentiation and promoted ATRA-induced autophagy and PML-RARα degradation.
- ATRA increased ROS, enhanced autophagic flux, and promoted HMGB1 translocation, which facilitated PML-RARα degradation via p62/SQSTM1 interactions.
Conclusions:
- HMGB1 is an essential regulator of ROS-induced APL cell differentiation.
- The interplay between ROS, HMGB1, autophagy, and p62/SQSTM1 is vital for PML-RARα degradation.
- HMGB1 represents a potential therapeutic target for APL treatment.
More Related Videos
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Lineage Commitment
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Abnormal Proliferation


